Xenograft News and Research

RSS

Xenograft are the cells of one species transplanted to another species.

Quark Pharmaceuticals' siRNAs examined alone and in xombination with chemotherapy

Quark Pharmaceuticals, Inc. has announced that the journal Cancer Research published results on efficacy of siRNA targeting its proprietary target gene against non-small cell lung cancer (NSCLC) in the edition dated October 1, 2008.

12 Oct 2008

Exelixis files investigational new drug application for anticancer compound

Exelixis, Inc. announced today that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for XL888, a novel anticancer compound. XL888 is an orally available small molecule inhibitor of HSP90, which is a chaperone protein that promotes the activity and stability of a range of key regulatory proteins, including kinases.

2 Oct 2008

Transapical aortic valve implantation

Transapical aortic valve implantation (TA-AVI) is a new therapeutic strategy, which has been implemented successfully into clinical practice in several hundred patients suffering symptomatic aortic stenosis and an increase perioperative risk during the past two years. The Edwards SAPIEN prosthesis has been used.

1 Sep 2008

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. That is, the suppression of circulating testosterone - the hormone that fuels prostate-cancer growth - via surgical castration (orchiectomy) or medical castration with testosterone-blocking drugs. While such therapy buys time for patients, it is not a cure, as inevitably the cancer becomes resistant to the androgen deprivation and continues to grow.

2 Jun 2008

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

1 Jun 2008

Cancer prevention

Tapping into a growing body of knowledge about the origins and progression of cancer, researchers are now developing and testing new preventive therapies to stop it in its tracks.

15 Apr 2008

FASgen announces new discoveries in lung cancer

FASgen is pleased to report the publication of important research results for lung cancer treatment using FAS093, one of the Company's proprietary compounds.

2 Jan 2008

Combination targets offer new hope in fight against cancer

While some targeted therapies - drugs developed to attack specific molecules in the critical chemical pathways occurring within cancer cells - work well by themselves, increasingly researchers are finding that they work better when teamed with other targeted and conventional therapies.

24 Oct 2007

Tumor cell receptor provides new therapeutic target

Working with a line of highly metastatic head and neck cancer cells, a research team at the Winship Cancer Institute and Emory University School of Medicine has found that a specific cell surface receptor present at very low levels in non-metastatic head and neck cancer cells.

27 Sep 2007

ADVENTRX announces positive data from multidrug therapy with cofactor

ADVENTRX Pharmaceuticals has announced positive results from preclinical studies using a multidrug treatment regimen including ANX-510 (CoFactor) at the American Association for Cancer Research (AACR) Annual Meeting.

19 Apr 2007

FASgen awarded grant for refinement of its serum fatty acid synthase

FASgen has announced that it has been awarded an SBIR grant from National Cancer Institute for refinement of its serum FAS (fatty acid synthase) ELISA cancer diagnostic test, FAS- Detect ELISA.

10 Apr 2007

Scientists discover new approach for treating virus-induced lymphomas

Kaposi's sarcoma herpesvirus (KSHV) is a human tumor virus and an etiological agent for Kaposi's sarcoma and primary effusion lymphoma (PEL). PELs are aggressive lymphomas with reported median survival time shorter than six months after diagnosis.

19 Mar 2007

Inhaled Celecoxib shows new promise for lung cancer treatment

In recent years, Cycloxygenase (COX)-2 has emerged as a therapeutic target for the prevention and treatment of various types of cancers.

6 Mar 2007

Researchers identify human pancreatic cancer stem cells

Researchers at the University of Michigan Medical Center have, for the first time, identified human pancreatic cancer stem cells. Their work indicates that these cells are likely responsible for the aggressive tumor growth, progression, and metastasis that define this deadly cancer.

1 Feb 2007

New treatment for the pediatric eye cancer retinoblastoma

Investigators at St. Jude Children's Research Hospital have demonstrated in laboratory studies a new treatment for the pediatric eye cancer retinoblastoma that appears to be more effective than the current standard therapy, and more likely to prevent the recurrence of this cancer. A report on their work appears in the October 15 issue of Clinical Cancer Research.

17 Oct 2005